Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Tiziana Life Sciences Ltd(TLSA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TLSA
09/28/2026: TLSA (1-star) is currently NOT-A-BUY. Pass it for now.
Tiziana Life Sciences is a clinical-stage biotechnology company focused on developing intranasal immunotherapies, specifically its lead asset foralumab, for neurodegenerative and autoimmune diseases. Its primary strength lies in its innovative drug delivery platform and a focused pipeline aimed at high-need medical areas. The company's investment story centers on the potential for its clinical trials to produce positive data that could lead to lucrative licensing agreements. However, it faces significant risks, including the lack of commercialized products, high cash burn, and intense competition from well-capitalized pharmaceutical giants. This stock is best suited for speculative investors comfortable with the high-risk, high-reward nature of early-stage biotech, with a focus on monitoring future clinical trial updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to biotech innovation but lacks revenue growth. |
| Momentum investor | Mixed fit | Momentum depends on clinical trial news and binary event catalysts. |
| Value investor | Weak fit | Lack of earnings and commercial products makes traditional value assessment inapplicable. |
| Dividend investor | Weak fit | The company is a clinical-stage entity that does not pay dividends. |
| Low-risk investor | Weak fit | High volatility and the risk of clinical failure make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical trial outcomes and financing news. |
| Valuation risk | Medium / high | Valuation is speculative and based on the potential success of future clinical data. |
| Competition risk (Major pharmaceutical incumbents) | High | The company competes against firms with far greater R&D and commercial resources. |
| Business quality | Medium | While the platform is novel, the company is still in the experimental development phase. |
| Dividend income | Low / none | No dividends are paid to shareholders. |
| Execution risk | High | Failure to achieve clinical endpoints or secure regulatory approval would severely impact the business. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -13.42% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 124.78M USD | Price to earnings Ratio - | 1Y Target Price 7.97 |
Price to earnings Ratio - | 1Y Target Price 7.97 | ||
Volume (30-day avg) 775.3K shares | Beta 0.45 | 52 Weeks Range 0.76 - 2.33 | Updated Date 09/28/2026 |
52 Weeks Range 0.76 - 2.33 | Updated Date 09/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research & Development | Clinical trial development for foralumab. | The company does not currently generate significant revenue and relies on equity capital to fund R&D. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 130.07M | Price to Sales(TTM) - |
Enterprise Value 130.07M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.98 | Shares Outstanding 127.26M | Shares Floating 61.89M |
Shares Outstanding 127.26M | Shares Floating 61.89M | ||
Percent Insiders 47.65 | Percent Institutions 1.94 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Tiziana Life Sciences Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2000-03-24 | CEO & Executive Director Dr. Ivor R. Elrifi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.